Please Wait...

Thorough QT/QTc Studies

Bioclinica offers full TQT study support, including concept and protocol design, ECG management and analysis and regulatory reporting. Bioclinica has supported innovative and conventional TQT trial designs in collaboration with members of sponsor and regulatory team members. We offer proven global capabilities and experience, having successfully completed the first ever regulatory mandated TQT study for a Japanese new drug application (NDA) and the first TQT study in China.

Bioclinica's Full TQT Services include:

  • Study design with full protocol and SAP development
  • Advanced ECG data capture, analysis methodologies and equipment
  • Analysis by US board-certified cardiologists
  • Expertise and guidance for regulatory submission (FDA, EMA, PMDA, and CFDA)
  • Quality assurance including customized reader variability reports
  • Interim cohort reporting
  • Support capabilities for data safety monitoring boards
  • Expert QT report writing
  • WebHeart platform for cardiac safety data management
  • Site training and continuous project support
  • Support in identifying clinical pharmacology research units

From a therapeutic and regulatory perspective, Bioclinica appreciates that not all compounds can complete a formal TQT. Our medical and scientific teams have the experience and regulatory awareness of how best to approach addressing the QT cardiac safety considerations where conventional TQT studies are not possible.

In today's heightened regulatory and R&D environment, it is imperative to partner with a core lab that can deliver quality and consistent ECG data and has capabilities and experience in the successful design, conduct and submission of TQT and intensive QT data.

ADDITIONAL RESOURCES

Thorough QT Studies

Download DATA SHEET

Cardiovascular Solutions

Download BROCHURE

Centralized ECG Services

Download DATA SHEET

Global Median Beat (GMB)

Download OVERVIEW SHEET

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Great advice from our Dir. Cardiovascular Imaging on how to achieve top quality imaging acquisitions & assessments… https://t.co/P57970FrOf
bioclinica (13 hours ago)
RT @CenterWatch: #CWWeekly: The increasing trend of adopting digital health and #mhealth apps for patient care. Read more, https://t.co/wo9…
bioclinica (14 hours ago)
RT @CenterWatch: Examining the difference between #patient engagement & patient recruitment. Read more in #CWPulse by @AshleyTointon, https…
bioclinica (14 hours ago)
RT @CenterWatch: How can #socialmedia play a role in health disparities and #clinicaltrial patient recruitment? Read more in #CWPulse by @A…
bioclinica (14 hours ago)
RT @RAPSorg: What New @FDAcdrhIndustry Guidance is Coming in FY 2018: Alternative 510(k) Pathway and More | #Regulatory Recon https://t.co/…
bioclinica (14 hours ago)
RT @RAPSorg: .@US_FDA Finalizes Guidance on Promotional Drug Labeling and Ads | #Regulatory Focus https://t.co/2rmtTWajlf #FDA #pharma
bioclinica (14 hours ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices